Leukemic mesenchymal stromal cell COX2-PG signaling regulates donor anti-leukemia immunity

Hematopoietic stem cell transplantation (HSCT) is considered the gold standard for treatment of hematologic malignancies, including Fanconi anemia (FA), a cancer-prone disease with extremely high incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, eradication of residual leukemia stem cells (LSCs), which often contributes to relapse, remains the challenge for HSCT. Here we investigate the interaction between leukemic mesenchymal niche and donor hematopoietic stem progenitor cells (HSPCs) by modeling FA HSCT.

Source: Experimental Hematology - August 22, 2017 Category: Hematology Authors: Wei Du, Limei Wu, Jian Xu, Sara MacLaughlin, Xue Li Source Type: research